William Spreen

9.3k total citations · 1 hit paper
80 papers, 3.6k citations indexed

About

William Spreen is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, William Spreen has authored 80 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Infectious Diseases, 52 papers in Virology and 18 papers in Epidemiology. Recurrent topics in William Spreen's work include HIV/AIDS drug development and treatment (59 papers), HIV Research and Treatment (52 papers) and HIV/AIDS Research and Interventions (38 papers). William Spreen is often cited by papers focused on HIV/AIDS drug development and treatment (59 papers), HIV Research and Treatment (52 papers) and HIV/AIDS Research and Interventions (38 papers). William Spreen collaborates with scholars based in United States, United Kingdom and Belgium. William Spreen's co-authors include Susan L. Ford, David A. Margolis, Stephen C. Piscitelli, Arlene R. Hughes, John C. Pottage, Michael Mosteller, Eric Lai, Elizabeth Gould, Allen D. Roses and David M. Margolis and has published in prestigious journals such as Science, The Lancet and Nature Medicine.

In The Last Decade

William Spreen

79 papers receiving 3.5k citations

Hit Papers

Genetic variations in HLA... 2002 2026 2010 2018 2002 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir
    2002 583 citations Seth Hetherington, Arlene R. Hughes et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
William Spreen 2.4k 1.8k 693 554 381 80 3.6k
Cassy Workman 1.2k 0.5× 1.3k 0.7× 359 0.5× 556 1.0× 514 1.3× 30 2.7k
Corey Moore 1.2k 0.5× 1.4k 0.8× 424 0.6× 658 1.2× 772 2.0× 19 2.9k
Andri Rauch 1.7k 0.7× 1.0k 0.6× 1.9k 2.7× 251 0.5× 410 1.1× 145 3.8k
Giampiero Carosi 947 0.4× 404 0.2× 554 0.8× 554 1.0× 225 0.6× 76 2.4k
David A. Cooper 5.5k 2.3× 4.4k 2.4× 1.6k 2.3× 205 0.4× 272 0.7× 118 7.1k
Hiroyuki Gatanaga 2.8k 1.2× 2.1k 1.2× 1.5k 2.2× 95 0.2× 764 2.0× 252 4.8k
Lawrence Deyton 2.2k 0.9× 1.9k 1.0× 762 1.1× 94 0.2× 259 0.7× 36 3.5k
Paul Jarosinski 1.1k 0.5× 622 0.3× 578 0.8× 142 0.3× 84 0.2× 35 2.4k
Hartwig Klinker 1.1k 0.5× 472 0.3× 1.6k 2.4× 113 0.2× 148 0.4× 157 2.9k
Brian P. Kearney 3.9k 1.7× 2.4k 1.3× 1.1k 1.7× 88 0.2× 100 0.3× 93 5.1k

Countries citing papers authored by William Spreen

Since Specialization
Citations

This map shows the geographic impact of William Spreen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Spreen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Spreen more than expected).

Fields of papers citing papers by William Spreen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Spreen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Spreen. The network helps show where William Spreen may publish in the future.

Co-authorship network of co-authors of William Spreen

This figure shows the co-authorship network connecting the top 25 collaborators of William Spreen. A scholar is included among the top collaborators of William Spreen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Spreen. William Spreen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
D’Amico, Ronald, Kelong Han, Sherene Min, et al.. (2025). Subcutaneous injections of cabotegravir plus rilpivirine long-acting in virally suppressed adults with HIV-1. AIDS. 39(15). 2182–2190. 1 indexed citations
2.
Daly, Michele B., Chuong Dinh, Angela Holder, et al.. (2024). SHIV remission in macaques with early treatment initiation and ultra long-lasting antiviral activity. Nature Communications. 15(1). 10550–10550.
3.
4.
Tan, Darrell H. S., Clifford Kinder, Cornelius N. Van Dam, et al.. (2024). Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir Alafenamide. JAIDS Journal of Acquired Immune Deficiency Syndromes. 98(4). 401–409. 4 indexed citations
5.
Patel, Parul, Susan L. Ford, Herta Crauwels, et al.. (2019). 2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies. Open Forum Infectious Diseases. 6(Supplement_2). S865–S866. 17 indexed citations
6.
Cong, Mian‐er, Susan Ruone, Alicia Newton, et al.. (2019). Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection. Nature Communications. 10(1). 2005–2005. 24 indexed citations
7.
Murray, Miranda, Martin Markowitz, Ian Frank, et al.. (2018). Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial. HIV Clinical Trials. 19(4). 129–138. 54 indexed citations
8.
Markowitz, Martin, Ian Frank, Robert M. Grant, et al.. (2017). Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. The Lancet HIV. 4(8). e331–e340. 164 indexed citations
9.
Andrews, Chasity D., Hiroshi Mohri, William Spreen, et al.. (2016). Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251. AIDS. 31(4). 461–467. 33 indexed citations
10.
Ford, Susan L., et al.. (2015). Formulation and pharmacology of long-acting cabotegravir. Current Opinion in HIV and AIDS. 10(4). 239–245. 142 indexed citations
11.
12.
Andrews, Chasity D., William Spreen, Hiroshi Mohri, et al.. (2014). Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus. Science. 343(6175). 1151–1154. 120 indexed citations
13.
Spreen, William, Susan L. Ford, Shuguang Chen, et al.. (2014). GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects. JAIDS Journal of Acquired Immune Deficiency Syndromes. 67(5). 481–486. 117 indexed citations
14.
Spreen, William, Peter Williams, David M. Margolis, et al.. (2014). Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults. JAIDS Journal of Acquired Immune Deficiency Syndromes. 67(5). 487–492. 96 indexed citations
15.
Spreen, William, Sherene Min, Susan L. Ford, et al.. (2013). Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor. HIV Clinical Trials. 14(5). 192–203. 92 indexed citations
16.
Spreen, William, David A. Margolis, & John C. Pottage. (2013). Long-acting injectable antiretrovirals for HIV treatment and prevention. Current Opinion in HIV and AIDS. 8(6). 565–571. 206 indexed citations
17.
Hammer, Scott M., Heather J. Ribaudo, Roland Bassett, et al.. (2010). A Randomized, Placebo-Controlled Trial of Abacavir Intensification in HIV-1–Infected Adults With Virologic Suppression on a Protease Inhibitor–Containing Regimen. HIV Clinical Trials. 11(6). 312–324. 16 indexed citations
18.
Hughes, Arlene R., William Spreen, Michael Mosteller, et al.. (2008). Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. The Pharmacogenomics Journal. 8(6). 365–374. 61 indexed citations
19.
Hughes, Sara, Arlene R. Hughes, Cindy Brothers, William Spreen, & D. Thorborn. (2007). PREDICT‐1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharmaceutical Statistics. 7(2). 121–129. 35 indexed citations
20.
Lederman, Michael M., Ray A. McKinnis, Dennis Kelleher, et al.. (2000). Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS. 14(17). 2635–2642. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cassy Workman Breakdown of academic impact, for papers by Corey Moore Breakdown of academic impact, for papers by Andri Rauch Breakdown of academic impact, for papers by Giampiero Carosi Breakdown of academic impact, for papers by David A. Cooper Breakdown of academic impact, for papers by Hiroyuki Gatanaga Breakdown of academic impact, for papers by Lawrence Deyton Breakdown of academic impact, for papers by Paul Jarosinski Breakdown of academic impact, for papers by Hartwig Klinker Breakdown of academic impact, for papers by Brian P. Kearney
Rankless by CCL
2026